BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Vrije Universiteit Amsterdam//NONSGML v1.0//EN
NAME:Inaugural lecture prof.dr. C.W. Menke - van der Houven van Oordt
METHOD:PUBLISH
BEGIN:VEVENT
DTSTART:20260116T154500
DTEND:20260116T171500
DTSTAMP:20260116T154500
UID:inaugural-lecture-prof-dr-c-w-@8F96275E-9F55-4B3F-A143-836282E12573
CREATED:20260826T070849
LOCATION:Main building VU, 1105, Aula, De Boelelaan, 1081 HV, Amsterdam
SUMMARY:Inaugural lecture prof.dr. C.W. Menke - van der Houven van Oordt
X-ALT-DESC;FMTTYPE=text/html: Zicht op de Patiënt
Improving diagnostics and treatments with molecular imag
ing
With molecular imaging, we use radioactively labeled subst
ances, so-called tracers, and the PET scan visualizes how these are d
istributed throughout the body. By using a tracer that detects hormon
e-sensitive breast cancer, we can, for example, improve diagnostics a
nd provide insight into the prognosis. This is what medical oncologis
t Willemien Menke-van der Houven van Oordt states in her inaugural le
cture.
This technology also allows us to track labeled drugs in
the patient and obtain information about optimal uptake in tumors an
d difficult-to-reach areas such as the brain. Such research is of gre
at value in the early development of new treatments, quickly determin
ing which drug has the best chance of success. In addition, we are de
veloping tracers for immune cells, which can visualize the effects of
(new) immunotherapies. The latest development concerns the labeling
of our newest immunotherapies, namely cell therapies, where we want t
o understand how these cells accumulate in tumors.
DESCRIPTION: Zicht op de Patiënt Improving diagnostics and treatm
ents with molecular imaging
With molecular imaging, we use radioa
ctively labeled substances, so-called tracers, and the PET scan visua
lizes how these are distributed throughout the body. By using a trace
r that detects hormone-sensitive breast cancer, we can, for example,
improve diagnostics and provide insight into the prognosis. This is w
hat medical oncologist Willemien Menke-van der Houven van Oordt state
s in her inaugural lecture.This technology also allows us to track la
beled drugs in the patient and obtain information about optimal uptak
e in tumors and difficult-to-reach areas such as the brain. Such rese
arch is of great value in the early development of new treatments, qu
ickly determining which drug has the best chance of success. In addit
ion, we are developing tracers for immune cells, which can visualize
the effects of (new) immunotherapies. The latest development concerns
the labeling of our newest immunotherapies, namely cell therapies, w
here we want to understand how these cells accumulate in tumors.
END:VEVENT
END:VCALENDAR